Risk-sharing in the Pharmaceutical Industry The Case of Out-licensing /
The costs of developing a new drug have reached record levels in the pharmaceutical industry. As any failure of a new drug candidate can lead to significant losses, many pharmaceutical companies are looking for new approaches to reduce their exposure to R&D risks. In this context, the book deals...
Αποθηκεύτηκε σε:
| Κύριος συγγραφέας: | |
|---|---|
| Συγγραφή απο Οργανισμό/Αρχή: | |
| Μορφή: | Ηλεκτρονική πηγή Ηλ. βιβλίο |
| Γλώσσα: | English |
| Έκδοση: |
Heidelberg :
Physica-Verlag HD : Imprint: Physica,
2006.
|
| Έκδοση: | 1st ed. 2006. |
| Σειρά: | Contributions to Management Science,
|
| Θέματα: | |
| Διαθέσιμο Online: | https://doi.org/10.1007/3-7908-1668-X |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|
Πίνακας περιεχομένων:
- Key Issues in Managing Pharmaceutical Innovation
- Risk-sharing as New Paradigm in Pharma R&D Collaborations
- Case Studies on Risk-sharing in Pharma R&D Collaborations
- Characteristics of Risk-sharing in Pharma R&D Collaborations
- Theoretical Basis for Risk-sharing in Pharma R&D Collaborations
- Managerial Recommendations for Risk-sharing in Pharma R&D Collaborations
- Conclusion.